The US FDA has granted priority review to an application for the use of Jemperli plus chemotherapy in adults with primary advanced or recurrent endometrial cancer. The application's scope is unclear, with some reports indicating it is for all adult patients, while others specify it is for those with dMMR/MSI-H endometrial cancer. There are also conflicting reports on whether Jemperli has been approved for the treatment of endometrial cancer.